Protagonist Therapeutics, Inc. (PTGX)
144.07
+1.07
(+0.75%)
USD |
NASDAQ |
Sep 21, 12:17
Protagonist Therapeutics Price to Book Value : 11.07 for Sept. 21, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 10.99 |
| September 17, 2026 | 11.04 |
| September 16, 2026 | 10.98 |
| September 15, 2026 | 11.02 |
| September 14, 2026 | 11.36 |
| September 11, 2026 | 11.39 |
| September 10, 2026 | 11.16 |
| September 09, 2026 | 11.15 |
| September 08, 2026 | 11.22 |
| September 04, 2026 | 11.20 |
| September 03, 2026 | 11.44 |
| September 02, 2026 | 11.23 |
| September 01, 2026 | 11.26 |
| August 31, 2026 | 11.35 |
| August 28, 2026 | 11.09 |
| August 27, 2026 | 11.49 |
| August 26, 2026 | 11.64 |
| August 25, 2026 | 11.57 |
| August 24, 2026 | 11.89 |
| August 21, 2026 | 11.86 |
| August 20, 2026 | 11.58 |
| August 19, 2026 | 11.91 |
| August 18, 2026 | 12.09 |
| August 17, 2026 | 12.19 |
| August 14, 2026 | 11.92 |
| Date | Value |
|---|---|
| August 13, 2026 | 11.64 |
| August 12, 2026 | 11.68 |
| August 11, 2026 | 11.40 |
| August 10, 2026 | 11.53 |
| August 07, 2026 | 11.21 |
| August 06, 2026 | 11.23 |
| August 05, 2026 | 10.55 |
| August 04, 2026 | 10.44 |
| August 03, 2026 | 10.17 |
| July 31, 2026 | 10.50 |
| July 30, 2026 | 10.65 |
| July 29, 2026 | 10.22 |
| July 28, 2026 | 10.52 |
| July 27, 2026 | 10.42 |
| July 24, 2026 | 10.46 |
| July 23, 2026 | 10.41 |
| July 22, 2026 | 10.41 |
| July 21, 2026 | 10.63 |
| July 20, 2026 | 10.32 |
| July 17, 2026 | 10.83 |
| July 16, 2026 | 10.15 |
| July 15, 2026 | 10.41 |
| July 14, 2026 | 10.09 |
| July 13, 2026 | 9.982 |
| July 10, 2026 | 10.10 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| Gilead Sciences, Inc. | 15.88 |
| Johnson & Johnson | 7.707 |
| Alnylam Pharmaceuticals, Inc. | 24.24 |
| BioMarin Pharmaceutical, Inc. | 1.967 |
Price to Book Value Related Metrics
| PE Ratio | 138.93 |
| PS Ratio | 34.40 |
| PEG Ratio | 3.050 |
| Price to Free Cash Flow | 74.28 |
| Price | 144.07 |
| Earnings Yield | 0.72% |
| Market Cap | 9.317B |
| PEGY Ratio | 3.050 |
| Operating PE Ratio | 166.25 |
| Normalized PE Ratio | 138.92 |